High dose calcitriol may reduce thrombosis in cancer patients

Tomasz M. Beer, Peter M. Venner, Christopher W. Ryan, Daniel P. Petrylak, Gurkamal Chatta, J. Dean Ruether, Kim N. Chi, John G. Curd, Thomas G. Deloughery

Research output: Contribution to journalArticlepeer-review

72 Scopus citations


The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0.01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.

Original languageEnglish (US)
Pages (from-to)392-394
Number of pages3
JournalBritish Journal of Haematology
Issue number3
StatePublished - Nov 2006


  • Calcitriol
  • Prostate cancer
  • Thromboembolism
  • Thrombosis
  • Vitamin D

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'High dose calcitriol may reduce thrombosis in cancer patients'. Together they form a unique fingerprint.

Cite this